• 250K

Information updates

EpiPen® Jr and EpiPen® supply update

November 23, 2017

Mylan has advised that both EpiPen 300mcg and EpiPen Jr 150mcg adrenaline (epinephrine) autoinjectors have now been shipped to Australian pharmacy wholesalers and stock will become available to pharmacies shortly. The supply of no-charge EpiPen® Jr 150mcg, expiring 30 November 2017, has therefore ceased. 

Further stock will be released over the coming weeks. Due to demand, orders will be filled as efficiently as possible, as they work to restore the supply.   

Please note that New Zealand has not been affected by these temporary supply issues.  

ASCIA recommends EpiPen® Jr 150mcg for patients weighing between 10-20kgs and EpiPen® 300mcg for patients 20kgs and over. 

Disclaimer and Privacy

The ASCIA website is intended for use by ASCIA members, other health professionals, the general public and media. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors and Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditation

healthdirect
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the
HONcode standard for
trustworthy health
 information.

Verify here.